Projects per year
Abstract
The title compound, C<inf>20</inf>H<inf>16</inf>N<inf>2</inf>O, (I), has been unwittingly obtained from the slow evaporation of a saturated solution of commercial benserazide hydrochloride [benserazide, (II), being one of the principal therapeutic compounds used for the management of Parkinson's disease, mostly used in combination with levodopa]. The molecule of (I) is composed of two planar 4-methyl-quinoline aromatic moieties [maximum deviations of 0.0104 (18) and 0.016 (2) Å], almost perpendicular to each other [dihedral angle = 89.5 (2)°], bridged by an O atom. The supramolecular organization consists of a π-bonded chain, resulting from the stacking of molecules related by inversion centres located along direction [111].
Original language | English |
---|---|
Pages (from-to) | 180-183 |
Number of pages | 4 |
Journal | Acta Crystallographica. Section E: Crystallographic Communications |
Volume | 71 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- Benser-azide
- Crystal structure
- Parkinson's disease
- Quinoline
- Therapeutic compounds
Fingerprint
Dive into the research topics of 'Crystal structure of 2, 2′-oxybis(4-methylquinoline)'. Together they form a unique fingerprint.Projects
- 1 Finished
-
API-ComB: Innovative formulation of high potential APIs : Solid-state efficient combination through cocrystallization
TILBORG, A.
1/10/13 → 30/06/15
Project: Research
Equipment
-
Physical Chemistry and characterization(PC2)
Johan Wouters (Manager) & Carmela Aprile (Manager)
Technological Platform Physical Chemistry and characterizationFacility/equipment: Technological Platform